# Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

> **NCT04611139** · PHASE1 · WITHDRAWN · sponsor: **HonorHealth Research Institute**

## Conditions studied

- SCCOHT
- Ovarian Clear Cell Tumor
- Ovarian Endometrioid Adenocarcinoma
- Endometrial Cancer

## Interventions

- **DRUG:** SP-2577
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04611139
- **Lead sponsor:** HonorHealth Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-31
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Salarius discontinued support
- **Last updated:** 2022-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04611139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04611139, "Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04611139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*